HUTCHMED (China) Limited American Depositary Shares

Over 30 pharmaceutical companies are developing BTK inhibitors targeting B-cell cancers, autoimmune disorders, and neurological conditions, with promising pipeline drugs in various clinical trial stages.

Hutchmed divests 45% equity in SHPL for $608 million, allowing it to focus on its core cancer drug development business. The company also received priority review for a lung cancer drug combination from China's NMPA.

HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After years of ‘lackluster’ efforts, regulators and companies are finally aligned in their goal to make clinical trials more representative of U.S. population.

The risks of investing in Chinese stocks are growing.